I realize that big pharmas are almost never interested in developing drugs from scratch but at the same time I can't possibly believe that small to moderate sized pharmas with nice cash positions, particularly if specializing in the neuro space, haven't looked at the boatloads of preclinical MANF data here, as well as early Voyager hype/success (and huge MC for a Phase I company), and not been intrigued.